Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Juno Therapeutics (JUNO)

Juno Therapeutics (JUNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Juno Therapeutics 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 USA

P: 206-582-1600

Description:

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.

Key Statistics

Overview:

Market Capitalization, $K 10,096,926
Shares Outstanding, K 116,110
Annual Sales, $ 79,360 K
Annual Net Income, $ -245,580 K
Last Quarter Sales, $ 44,820 K
Last Quarter Net Income, $ -118,130 K
60-Month Beta 3.24
% of Insider Shareholders 15.08%
% of Institutional Shareholders 70.19%

Growth:

1-Year Return 302.41%
3-Year Return 75.71%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.73 on 11/01/17
Next Earnings Date 03/07/18
Earnings Per Share ttm -3.25
EPS Growth vs. Prev Qtr -49.33%
EPS Growth vs. Prev Year -93.10%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

JUNO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -17.99
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -32.54
Return-on-Assets (Before Tax) -24.87
Profit Margin % -309.45
Net Margin % N/A
Debt/Equity 0.01
Price/Sales 82.93
Price/Cash Flow N/A
Price/Book 9.58
Book Value/Share 10.28
Interest Coverage N/A
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar